The PASEO (PaclitAxel or Sirolimus-Eluting Stent Versus Bare Metal Stent in Primary Angioplasty) Randomized Trial
|
|
- Magnus Gallagher
- 5 years ago
- Views:
Transcription
1 JACC: CARDIOVASCULAR INTERVENTIONS VOL. 2, NO. 6, BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN /09/$36.00 PUBLISHED BY ELSEVIER INC. DOI: /j.jcin The PASEO (PaclitAxel or Sirolimus-Eluting Stent Versus Bare Metal Stent in Primary Angioplasty) Randomized Trial Emilio Di Lorenzo, MD, PHD,* Giuseppe De Luca, MD, PHD, Rosario Sauro, MD,* Attilio Varricchio, MD, PHD,* Michele Capasso, MD,* Tonino Lanzillo, MD,* Fiore Manganelli, MD,* Ciro Mariello, MD,* Francesco Siano, MD,* Maria Rosaria Pagliuca, MD,* Giovanni Stanco, MD,* Giuseppe Rosato, MD* Avellino and Novara, Italy Objectives The aim of this study was to evaluate the benefits of sirolimus-eluting stents (SES) and paclitaxeleluting stents (PES) as compared with bare-metal stents (BMS) in patients undergoing primary angioplasty. Background Recent concerns have emerged on the potential higher risk of stent thrombosis after drugeluting stent implantation, especially among ST-segment elevation myocardial infarction (STEMI) patients. Methods We randomly assigned STEMI patients admitted within 12 h of symptom onset undergoing primary angioplasty and stent implantation to BMS, PES, or SES. The primary study end point was target lesion revascularization at 1-year follow-up. All patients were reviewed at our outpatient clinic or by telephone interview at 6, 12, and 24 months. Results From October 2003 to December 2005, 270 STEMI patients undergoing primary angioplasty were randomized to BMS (n 90), PES (n 90), or SES (n 90). No patient was lost to follow-up. As compared with BMS (14.4%), both PES (4.4%, p 0.023) and SES (3.3%, p 0.016) were associated with a significant reduction in target lesion revascularization at 1-year follow-up. At 2-year follow-up no difference was observed in terms of death, reinfarction, and combined death and/or reinfarction, but as compared with BMS, both PES and SES were associated with significant benefits in major adverse cardiac events (PES: 16.7%, p 0.015; SES: 15.6%, p 0.009, respectively). Conclusions This study shows that among STEMI patients undergoing primary angioplasty, both SES and PES are safe and associated with significant benefits in terms of target lesion revascularization up to the 2-year follow-up. Thus, until the results of further large randomized trials with longterm follow-up become available, drug-eluting stents may be considered for STEMI patients undergoing primary angioplasty. (PaclitAxel or Sirolimus-Eluting Stent versus Bare Metal Stent in Primary Angioplasty [PASEO] Randomized Trial; NCT ) (J Am Coll Cardiol Intv 2009;2:515 23) 2009 by the American College of Cardiology Foundation From the *Division of Cardiology, Ospedale S.G. Moscati, Avellino, Italy; Division of Cardiology, Ospedale Maggiore della Carità, and Centro di Biotecnologie per la Ricerca Medica Applicata (BRMA), Eastern Piedmont University, Novara, Italy. Drs. Di Lorenzo and De Luca contributed equally to this study. Manuscript received February 12, 2009, accepted March 17, 2009.
2 516 JACC: CARDIOVASCULAR INTERVENTIONS, VOL. 2, NO. 6, 2009 Abbreviations and Acronyms BMS bare-metal stent(s) DES drug-eluting stent(s) PCI percutaneous coronary intervention PES paclitaxel-eluting stent(s) SES sirolimus-eluting stent(s) STEMI ST-segment elevation myocardial infarction TLR target lesion revascularization TVR target vessel revascularization Primary percutaneous coronary intervention (PCI), when performed expeditiously and expertly, has been shown to be superior to thrombolytic therapy in the treatment of patients with ST-segment elevation myocardial infarction (STEMI) (1). Although, as compared with balloon angioplasty, stent implantation has reduced the occurrence of restenosis in selected STEMI patients (2,3), the outcome of bare-metal stents (BMS) seem to be worse in unselected patients with a rate of target vessel revascularization (TVR) up to 20% (4,5). Several randomized trials have shown that drugeluting stents (DES), compared with BMS, are associated with a significant reduction in restenosis and TVR in elective patients (6 10). However, recent concerns have emerged on the potential higher risk of stent thrombosis with DES (11 14) that might be even more pronounced among STEMI patients, as suggested by a prospective registry (15). The aim of the current study was to evaluate the benefits of sirolimus-eluting stents (SES) and paclitaxeleluting stents (PES) as compared with the benefits of BMS in patients undergoing primary angioplasty for STEMI. Methods The PASEO (PaclitAxel or Sirolimus-Eluting Stent versus Bare Metal Stent in Primary Angioplasty) trial was a prospective, single-center, randomized trial evaluating the benefits of SES or PES as compared with BMS implantation in patients undergoing primary angioplasty for acute STEMI. Individuals eligible for enrollment were patients presenting with STEMI who fulfilled all the following inclusion criteria: 1) chest pain for more than 30 min; 2) ST-segment elevation of 1 mm or more in 2 or more contiguous electrocardiograph leads or with presumably new left bundle branch block; 3) hospital admission within 12 h from symptoms onset. Exclusion criteria included: 1) active internal bleeding or a history of bleeding diathesis within the previous 30 days; 2) history of intracranial hemorrhage, intracranial neoplasm, arteriovenous malformation or aneurysm; 3) known allergy to sirolimus, paclitaxel, heparin, aspirin, or clopidogrel; 4) history of stroke within 30 days or any history of hemorrhagic stroke; 5) major surgical procedure or severe physical trauma within the previous month; 6) history, symptoms, or findings suggestive of aortic dissection; 7) thrombolytic/fibrinolytic therapy within 24 h; 8) history of thrombocytopenia; 9) hemorrhagic retinopathy; 10) patients on warfarin or acenocoumarol with international normalized ratio 2; and 11) pregnancy. Previous gastrointestinal ulcer or gastrointestinal bleeding were not exclusion criteria. A vessel size 2.25 mm was the only angiographic exclusion criteria. The institutional review board of the Ospedale S.G. Moscati (Avellino, Italy) approved the protocol in 2003, and all patients gave written informed consent. Open-label randomization was performed in the catheterization laboratory after initial angiography by the treating physician when eligibility criteria were met. A 1:1:1 computer-generated random sequence, without blocking or stratification, was used. Sealed envelopes indicated the treatment group to which the patients were assigned: SES, PES, or BMS. Medications. In the coronary care unit, all patients received 70 U/kg intravenous bolus of unfractionated heparin plus 1000 U/h infusion (to maintain an activated clotting time of at least 200 s), aspirin intravenously (500 mg), and clopidogrel (300-mg loading dose). All patients received upstream glycoprotein IIb/IIIa inhibitors as a routine adjunctive therapy before primary PCI. Post-interventional antiplatelet therapy for all patients included in the 3 study groups consisted of aspirin (100 mg) indefinitely and clopidogrel (75 mg for 6 months). Angioplasty procedure. Stenting procedures were performed according to standard techniques. The number, size, and length of stents (based on online quantitative angiographic analyses), and the type of BMS to be implanted, were left to the operator s discretion. In cases of DES implantation, it was recommended to cover the entire length of the lesion with additional coverage of 5 mm proximal and distal to the lesion. The use of intravascular ultrasound, adjunctive thrombectomy devices, distal protection devices, and intra-aortic balloon pump were left to the operator s discretion. Angiographic analysis. Thrombolysis In Myocardial Infarction (TIMI) flow grade 3 coronary flow in the treated vessel and a residual stenosis less than 30% were the criteria used to define a successful PCI. Offline quantitative coronary angiography (Integris Allura, Philips, Best, the Netherlands) were performed by 2 experienced technicians who were unaware of treatment assignment with the averaging scores if they were not in agreement. The target lesion was defined as the stented segment plus the 5-mm segments immediately proximal and distal to the stent. Data collection and follow-up. All patients were reviewed at our outpatient clinic or by telephone interview at 6, 12, and 24 months. A stress test was performed at 6 to 8 months and subsequently yearly. For patients who died during followup, hospital records and necropsy data were reviewed when possible. No patient was lost to follow-up. Study end points and definitions. The primary end point was target lesion revascularization (TLR) at 1-year follow-up. Secondary end points were: 1) cumulative combined incidence of death and/or recurrent MI at 2-year follow-up; 2)
3 JACC: CARDIOVASCULAR INTERVENTIONS, VOL. 2, NO. 6, Figure 1. Study Flow Chart The figure shows how patients were assigned to specific stent treatment groups. BMS bare-metal stent(s); PES paclitaxel-eluting stent(s); pts patients; SES sirolimus-eluting stent(s); STEMI ST-segment elevation myocardial infarction. cumulative incidence of in-stent thrombosis (assessed according to Academic Research Consortium s definition [16]) at 2-year follow-up; and 3) major adverse cardiac events (combined death and/or recurrent MI and/or TLR) at 2-year follow-up. All deaths were considered cardiac unless an unequivocal noncardiac cause could be identified. Recurrent MI was defined as recurrence of anginal symptoms with typical electrocardiographic changes and increase above the upper limit of normal of creatine kinase-myocardial band or troponin. The indication for a second intervention had to be substantiated by symptoms or by electrocardiographic or scintigraphic evidence of ischemia at rest or during exercise. Subsequent revascularization of other coronary arteries did not constitute an end point. All events were reviewed by 2 cardiologists blinded to treatment assignment. Statistical analysis. Statistical analysis was performed using SPSS version 15.0 (SPSS Inc., Chicago, Illinois). Continuous data were expressed as mean (SD) and categorical data as percentages. Data were analyzed according to intentionto-treat analysis (SES vs. BMS and PES vs. BMS). The analysis of variance or the Mann-Whitney U test were appropriately used for continuous variables. (Normal distribution was assessed by the Kolmogorov-Smirnov test.) The chi-square test or Fisher exact test was used for categorical variables The difference in event rates between groups during the follow-up period was assessed by the Kaplan- Meier method with the log-rank test. A probability value of p (with Bonferroni correction) was considered significant. SAMPLE SIZE CALCULATION. According to recent reports (4,5), we estimated a rate of TLR at 1 year of 20% in the BMS group. With an anticipated 2-sided test for differences in independent binomial proportions at the 2.5% significance level (with Bonferroni correction) with a power of 80%, 89 patients were necessary to detect a reduction in a primary end point of 80% (from 20% to 4%) with DES (PES and SES, respectively). The number of patients was extended to 90 per group. Results Patient population. From October 1, 2003, to December 31, 2005, 270 patients with STEMI undergoing primary angioplasty and stent implantation were randomized to BMS (n 90), PES (n 90), or SES (n 90) treatment. A trial flow diagram is shown in Figure 1. As reported in Tables 1 and 2, no difference was observed in terms of baseline demographic, clinical, and angiographic characteristics among the groups. Procedural results. As shown in Table 2, no difference was observed in terms of angiographic and procedural characteristics. Almost 50% of patients underwent PCI of left anterior descending artery. All patients received upstream glycoprotein IIb/IIIa inhibitors. Procedural success was obtained in 93% to 95% of patients. A direct stenting strategy was adopted in 24% to 29% of patients. In the PES group, we observed a higher number of stents per patient ( vs , p 0.036). Clinical outcome at 1-year follow-up. Follow-up data were available for all patients. Almost all patients stopped clopidogrel therapy at 6-month follow-up (Table 3). As reported in Table 4, at 1-year follow-up, no difference was observed in terms of death (6 deaths in BMS patients due to: heart failure [n 3], sudden death [n 1], reinfarction [n 1], cardiac surgery [n 1]; 4 deaths in PES patients due to: sudden death [n 2], reinfarction [n 2]; 3 deaths in SES patients due to: sudden death [n 2], reinfarction [n 1]), reinfarction, and combined death and/or reinfarction. One stent thrombosis was documented in both the BMS (1.1%) and PES (1.1%) groups, both of them within 30 days from primary PCI, whereas no case of stent thrombosis was observed after 30 days. As compared with BMS (14.4%),
4 518 JACC: CARDIOVASCULAR INTERVENTIONS, VOL. 2, NO. 6, 2009 Table 1. Baseline Demographic and Clinical Characteristics of the 3 Groups of Patients Variable BMS (n 90) PES (n 90) p Value SES (n 90) p Value Age, yrs Male, % Hypertension, % Diabetes, % IDDM NIDDM Smoking, % Previous MI, % Previous CABG, % Previous PCI, % Cardiogenic shock, % Anterior MI, % Ejection fraction 40%, % Ischemia time, min Door-to-balloon time, min BMS bare-metal stent(s); CABG coronary artery bypass graft; IDDM insulin-dependent diabetes mellitus; MI myocardial infarction; NIDDM noninsulin-dependent diabetes mellitus; PES paclitaxel-eluting stent(s); PCI percutaneous coronary intervention; SES sirolimus-eluting stent(s). both PES (4.4%, hazard ratio [HR] [95% confidence interval (CI)]: 0.29 [0.095 to 0.89], p 0.023) and SES (3.3%, HR [95% CI]: 0.21 [0.06 to 0.75], p 0.016) were associated with a significant reduction in TLR (primary study end point). Finally, as compared with BMS (24.4%), both PES and SES were associated with significant benefits Table 2. Angiographic and Procedural Characteristics of the 3 Groups of Patients Variable BMS (n 90) PES (n 90) p Value SES (n 90) p Value IRA, % LAD LCX RCA Pre-procedural TIMI flow grade, % Post-procedural TIMI flow grade, % RD, mm % stenosis before % stenosis after Stent diameter, mm Max stent diameter, mm Total stent length, mm Number of stents stent, % Direct stenting, % Maximal balloon inflation, atm Procedural success, % GP IIb/IIIa inhibitors, % Thrombectomy devices, % GP glycoprotein; IRA infarct-related artery; LAD left anterior descending artery; LCX left circumflex artery; RCA right coronary artery; RD reference diameter; TIMI Thrombolysis In Myocardial Infarction; other abbreviations as in Table 1.
5 JACC: CARDIOVASCULAR INTERVENTIONS, VOL. 2, NO. 6, Table 3. Medical Therapy of the 3 Groups of Patients Variable BMS (n 90) PES (n 90) p Value SES (n 90) p Value Aspirin, % Beta-blockers, % ACE inhibitors, % Statins, % Clopidogrel at discharge, % Clopidogrel administration, days Clopidogrel at 30 days, % months, % ACE angiotensin-converting enzyme; other abbreviations as in Table 1. in major adverse cardiac events (PES: 11.1%, HR [95% CI]: 0.42 [0.2 to 0.9], p 0.02; SES: 11.1%, HR [95% CI]: 0.42 [0.2 to 0.89], p 0.02). Clinical outcome at 2-year follow-up. Follow-up data were available in all patients. As reported in Table 4, at 2-year follow-up, no difference was observed in terms of death (Fig. 2) (9 deaths in BMS patients due to: heart failure [n 4], sudden death [n 2], cardiac surgery [n 1], reinfarction [n 2]; 6 deaths in PES patients due to: sudden death [n 2], reinfarction [n 2]; cardiogenic shock [n 2]; 5 deaths in SES patients due to: sudden death [n 2], reinfarction [n 2], noncardiac death [n 1]), reinfarction (Fig. 3), and combined death and/or reinfarction (secondary study end point) (PES: 12.2%, HR [95% CI]: 0.63 [0.29 to 1.34], p 0.17; SES: 11.1%, HR [95% CI]: 0.57 [0.26 to 1.23], p 0.27), as compared with BMS (18.3%) (Fig. 4). No additional case of in-stent thrombosis was observed up to 2-year follow-up. As compared with BMS (17.8%), both PES (5.6%, HR [95% CI]: 0.29 [0.11 to 0.8], p 0.01) and SES (4.4%, HR [95% CI]: 0.23 [0.076 to 0.68], p 0.004) were associated with a significant reduction in TLR (Fig. 5). Finally, as compared with BMS (32.2%), both PES and SES were associated with significant benefits in overall MACE (secondary study end point) (PES: 16.7%, HR [95% CI]: 0.47 [0.25 to 0.88], p 0.015; SES: 15.6%, HR [95% CI]: 0.44 [0.23 to 0.83], p 0.005) (Fig. 6). Table 4. Clinical Outcome at 1-Year Follow-Up Variable BMS (n 90) PES (n 90) p Value PES vs. BMS HR [95% CI] SES (n 90) p Value SES vs. BMS HR [95% CI] 1-year outcome Death, % [ ] [ ] remi, % [ ] [ ] Death and/or remi, % [ ] [ ] TLR, % [ ] [ ] Definite IST, % [ ] [ ] Early ( 30 days) [ ] [ ] Late ( 30 days) Total IST,* % [ ] [ ] MACE, % [ ] [ ] 2-year outcome Death [ ] [ ] ReMI, % [ ] [ ] Death and/or remi, % [ ] [ ] TLR, % [ ] [ ] Definite IST, % [ ] [ ] Very late IST ( 1 year) Total IST* [ ] [ ] MACE, % [ ] [ ] *Definite, probable, and possible in-stent thrombosis. CI confidence interval; HR hazard ratio; IST angiographic in-stent thrombosis; MACE major adverse cardiac events; remi reinfarction; TLR target lesion revascularization; other abbreviations as in Table 1.
6 520 JACC: CARDIOVASCULAR INTERVENTIONS, VOL. 2, NO. 6, 2009 Figure 2. Kaplan-Meier Survival Curves for Death Comparing BMS, PES, and SES Kaplan-Meier survival curves comparing BMS with PES (p 0.84) and SES (p 0.52). Abbreviations as in Figure 1. prospective multicenter primary angioplasty registry (PRE- MIER [Prospective Registry Evaluating Myocardial Infarction Events and Recovery]), the use of DES rather than BMS was associated with higher risk of mortality within the first 6 months (presumably due to higher stent thrombosis), particularly in the case of early discontinuation of double oral antiplatelet therapy (18). In fact, unlike with elective patients, it may be difficult to forecast future long-term patients compliance at the time of intervention among STEMI patients (18). Several randomized trials have been conducted so far in STEMI (19 35). Valgimigli et al. (19) compared SES plus tirofiban with the bare-metal Bx Velocity (Cordis Corp., Bridgewater, New Jersey) plus abciximab in 175 STEMI patients. At 8-month follow-up, SES was associated with a significant reduction in TVR (7% vs. 20%, p 0.01), with a similar outcome in terms of death (2% vs. 3%, p NS), reinfarction (1% vs. 3%, p NS), and stent thrombosis (0% vs. 2%, p NS). Similar benefits have been observed in the larger MULTISTRATEGY (Multicentre Evaluation of Single High-Dose Bolus Tirofiban versus Abciximab with Sirolimus-Eluting Stent or Bare Metal Stent in Acute Myocardial Infarction Study) trial (32). The benefits from SES in terms of reducing clinical and angiographic restenosis without an increase in death or MI have been confirmed in subsequent moderate-sized randomized trials Discussion To the best of our knowledge, this is the first randomized study evaluating the benefits and safety of both PES and SES versus BMS in patients undergoing primary angioplasty for STEMI at long-term follow-up (2 years). The main finding of the current study is that PES and SES are safer and more effective than BMS, mainly due to a reduction in TLR. After the initial safety concerns, numerous studies and randomized trials have demonstrated the safety and efficacy of stenting in the setting of STEMI (3). A recent comprehensive meta-analysis in patients undergoing primary PCI has shown the benefits of stenting compared with balloon angioplasty alone in terms of reducing TVR, though no definite affect on death and reinfarction was present (3). However, restenosis rates after BMS in STEMI patients are still high, especially in unselected patients with complex lesion morphology (4,5). Several randomized trials have shown that, among elective patients, DES are associated with a significant reduction in restenosis and TVR (6 10). However, recent concerns have emerged regarding an increased risk of late thrombosis stent associated with DES (12 15). As most episodes of stent thrombosis result in MI, this increase with DES may impact mortality, particularly after primary angioplasty, as reinfarction is a major determinant of survival (17). In a recent Figure 3. Kaplan-Meier Event-Free Survival Curves for Reinfarction Comparing BMS, PES, and SES Kaplan-Meier event-free survival curves for reinfarction comparing BMS with PES (p 0.34) and SES (p 0.58). Abbreviations as in Figure 1.
7 JACC: CARDIOVASCULAR INTERVENTIONS, VOL. 2, NO. 6, Figure 4. Kaplan-Meier Event-Free Survival Curves (for Death and/or Reinfarction) Comparing BMS, PES, and SES Kaplan-Meier event-free survival curves (for death and/or reinfarction) comparing BMS with PES (p 0.44) and SES (p 0.29). Abbreviations as in Figure 1. Acute Myocardial Infarction) trial (32), including more than 3,000 STEMI patients, that have shown significant benefits in terms of TLR with Taxus (Boston Scientific) stents as compared with BMS (4.5% vs. 7.5%, respectively), with similar outcome in terms of death and reinfarction. However, almost all currently available trials have provided relatively short-term follow-up data (not longer than 12 months), whereas late stent thrombosis has been described up to 1 to 2 years after clopidogrel discontinuation. The STRATEGY (Single High-Dose Bolus Tirofiban and Sirolimus-Eluting Stent vs. Abciximab and Bare-Metal Stent in Myocardial Infarction) trial is the only trial published so far with 2-year follow-up data, showing long-term safety and benefits of SES as compared with BMS (33). In our study, including a larger population, we demonstrated the long-term safety and benefits of both SES and PES as compared with BMS. Of relevance, unlike the vast majority of randomized trials so far conducted, in our trial, the superiority of SES and PES was observed without use of routine angiographic follow-up. Large randomized trials, with longer follow-up data are certainly needed to further investigate the long-term safety of DES in primary angioplasty. In this regard, important information is expected to be derived from the HORIZONS- AMI trial (34). such as the TYPHOON (Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated with Angioplasty), SESAMI (Sirolimus-Eluting Stent Versus Bare-Metal Stent in Acute Myocardial Infarction), and MISSION trials (21,22,27). In the PASSION (Paclitaxel-Eluting Stent versus Conventional Stent in ST-Segment Elevation Myocardial Infarction ) trial (20), Laarman et al. compared PES versus Express (Boston Scientific, Natick, Massachusetts) stents in 619 STEMI patients. Despite the safety of PES in terms of death (4.6% vs. 6.5%, p NS) and stent thrombosis (1% vs. 1%, p NS) at 1-year follow-up, as compared with BMS, only a weak trend was present toward a reduction in TLR (5.3% vs. 7.8%, p NS). The relatively less favorable outcomes of PES in this trial compared with the outcomes of SES in the previous trials may relate either to the less marked reduction of neointimal hyperplasia with paclitaxel versus sirolimus, or a better outcome with the control stents in the PASSION trial compared with the Bx Velocity stents in the SES trials. Also of note, routine angiographic follow-up was not performed in the PASSION trial. In fact, several reports have demonstrated that routine angiographic follow-up is associated with a larger rate of TVR, even in the era of DES (36). Similar findings have been observed in the recently conducted large HORIZONS AMI (Harmonizing Outcomes with Revascularization and Stents in Figure 5. Kaplan-Meier Event-Free Survival Curves for TLR Comparing BMS, PES, and SES Kaplan-Meier event-free survival curves for target lesion revascularization (TLR) comparing BMS with PES (p 0.02) and SES (p 0.008). Abbreviations as in Figure 1.
8 522 JACC: CARDIOVASCULAR INTERVENTIONS, VOL. 2, NO. 6, 2009 Reprint requests and correspondence: Dr. Emilio Di Lorenzo, Division of Cardiology, Laboratory of Cardiac Catheterization and Interventional Cardiology, S.G. Moscati Hospital, Via Otranto, Avellino, Italy. REFERENCES Figure 6. Kaplan-Meier Event-Free Survival Curves for MACE Comparing BMS, PES, and SES Kaplan-Meier event-free survival curves for major adverse cardiac events (MACE) comparing BMS with PES (p 0.03) and SES (p 0.018). Abbreviations as in Figure 1. Study limitations. Due to a relatively late randomization strategy (after initial angiography), patients have for the most part been selected, and thus the conclusion of this trial cannot be extended to all patients undergoing primary angioplasty for STEMI. Even though small vessels (2.25 to 2.5 mm) were not excluded, our patient population had a relatively larger (3.1 mm) mean reference diameters than were included in previous randomized trials. Furthermore, to avoid any bias due to length of clopidogrel prescription, we preferred to prescribe clopidogrel up to 6 months in BMS patients as well. Despite long-term follow-up data, due to the relatively small sample size, this trial cannot provide definite conclusions on DES safety in terms of death and reinfarction that will be hopefully provided by large randomized trials. Conclusions This study shows that among STEMI patients undergoing primary angioplasty, both SES and PES are safe and associated with significant benefits in terms of TLR up to 2-year follow-up. Thus, until the results of further large randomized trials with long-term follow-up become available, DES may be considered for use for STEMI patients undergoing primary angioplasty. 1. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003;361: Stone GW, Grines CL, Cox DA, et al., on behalf of Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Investigators. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002;346: De Luca G, Suryapranata H, Stone GW, et al. Coronary stenting versus balloon angioplasty for acute myocardial infarction: a metaregression analysis of randomized trials. Int J Cardiol 2008;126: Antoniucci D, Migliorini A, Parodi G, et al. Abciximab-supported infarct artery stent implantation for acute myocardial infarction and long-term survival: a prospective, multicenter, randomized trial comparing infarct artery stenting plus abciximab with stenting alone. Circulation 2004;109: Suryapranata H, De Luca G, van t Hof AW, et al. Is routine stenting for acute myocardial infarction superior to balloon angioplasty? A randomised comparison in a large cohort of unselected patients. Heart 2005;91: Moses JW, Leon MB, Popma JJ, et al., on behalf of SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349: Stone GW, Ellis SG, Cox DA, et al., on behalf of TAXUS-IV Investigators. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350: Ardissino D, Cavallini C, Bramucci E, et al., on behalf of SES- SMART Investigators. Sirolimus-eluting vs uncoated stents for prevention of restenosis in small coronary arteries: a randomized trial. JAMA 2004;292: Colombo A, Moses JW, Morice MC, et al. Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions. Circulation 2004;109: Roiron C, Sanchez P, Bouzamondo A, Lechat P, Montalescot G. Drug eluting stents: an updated meta-analysis of randomised controlled trials. Heart 2006;92: Schömig A, Dibra A, Windecker S, et al. A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease. J Am Coll Cardiol 2007;50: McFadden EP, Stabile E, Regar E, et al. Late thrombosis in drugeluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004;364: Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005;293: Lagerqvist B, James SK, Stenestrand U, et al., on behalf of SCAAR Study Group. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 2007;356: Kernis SJ, Cohen D, Rein K. Clinical outcome associated with use of drug-eluting stents compared with bare metal stent for primary percutaneous intervention (abstr). Am J Cardiol 2005;96 Suppl 7A: 47H. 16. Cutlip DE, Windecker S, Mehran R, et al., on behalf of Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007;115: De Luca G, Ernst N, van t Hof AW, et al. Predictors and clinical implications of early reinfarction after primary angioplasty for STsegment elevation myocardial infarction. Am Heart J 2006;151:
9 JACC: CARDIOVASCULAR INTERVENTIONS, VOL. 2, NO. 6, Spertus JA, Kettelkamp R, Vance C, et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation 2006;113: Valgimigli M, Campo G, Percoco G, et al., on behalf of Multicentre Evaluation of Single High-Dose Bolus Tirofiban vs Abciximab With Sirolimus-Eluting Stent or Bare Metal Stent in Acute Myocardial Infarction Study (MULTISTRATEGY) Investigators. Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial. JAMA 2005;293: Laarman GJ, Suttorp MJ, Dirksen MT, et al. Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. N Engl J Med 2006;355: Spaulding C, Henry P, Teiger E, et al., on behalf of TYPHOON Investigators. Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med 2006;355: Menichelli M, Parma A, Pucci E, et al. Randomized trial of Sirolimus- Eluting Stent Versus Bare-Metal Stent in Acute Myocardial Infarction (SESAMI). J Am Coll Cardiol 2007;49: Pittl U, Kaiser C, Brunner-La Rocca HP, on behalf of BASKET Investigators. Safety and efficacy of drug eluting stents versus bare metal stents in primary angioplasty of patients with acute ST-elevation myocardial infarction a prospective randomized study (abstr). Eur Heart J 2006;27 Suppl: Sardella G, Paroli M, Mancone M. Impact of paclitaxel-eluting stent implantation in patients with STEMI on anti-inflammatory IL-10- producing T regulatory 1 (Tr1) cells (abstr). Eur Heart J 2006;27 Suppl: Pasceri V, Granatelli A, Pristipino C. A randomized trial of a rapamycin-eluting stent in acute myocardial infarction: preliminary results. Am J Cardiol 2003;92 Suppl 6A:1L. 26. Tierala I. The Helsinki Area Acute Myocardial Infarction treatment re-evaluation should the patient get a drug-eluting or a normal stent (HAAMU-STENT) study. Available at: csportal/appmanager/tctmd/main?_nfpb true&_pagelabel TCTMDContent&hdCon Accesssed November 7, van der Hoeven BL, Liem SS, Jukema JW, et al. Sirolimus-eluting stents versus bare-metal stents in patients with ST-segment elevation myocardial infarction: 9-month angiographic and intravascular ultrasound results and 12-month clinical outcome results from the MIS- SION! Intervention Study. J Am Coll Cardiol 2008;51: Díaz de la Llera LS, Ballesteros S, Nevado J, et al. Sirolimus-eluting stents compared with standard stents in the treatment of patients with primary angioplasty. Am Heart J 2007;154:164.e Chechi T, Vittori G, Biondi Zoccai GG, et al. Single-center randomized evaluation of paclitaxel-eluting versus conventional stent in acute myocardial infarction (SELECTION). J Interv Cardiol 2007;20: Kelbaek H, Theusen L, Helqvist S, et al. Drug-eluting vs. bare metal stents in patients with ST-segment elevation myocardial infarction: eight-month follow-up in the drug-elution and distal protection in acute myocardial infarction (DEDICATION) trial. Circulation 2008; 118: Karjalainen PP, Ylitalo A, Niemala M, et al. Titanium-nitride-oxide coated stents versus paclitaxel-eluting stents in acute myocardial infarction: a 12-month follow-up report from the TITAX AMI trial. EuroIntervention 2008;4: Valgimigli M, Campo G, Percoco G, et al., on behalf of Multicentre Evaluation of Single High-Dose Bolus Tirofiban vs Abciximab With Sirolimus-Eluting Stent or Bare Metal Stent in Acute Myocardial Infarction Study (MULTISTRATEGY) Investigators. Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial. JAMA 2008; 299: Valgimigli M, Campo G, Arcozzi C, et al. Two-year clinical follow-up after sirolimus-eluting versus bare-metal stent implantation assisted by systematic glycoprotein IIb/IIIa Inhibitor Infusion in patients with myocardial infarction: results from the STRATEGY study. J Am Coll Cardiol 2007;50: Stone GW, Lansky A, Pocock SJ, et al. Paclitaxel-eluting stent versus bare-metal stents in acute myocardial infarction. N Engl J Med 2008;360: Kastrati A, Dibra A, Spaulding C, et al. Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction. Eur Heart J 2007;28: Pinto DS, Stone GW, Ellis SG, et al., on behalf of TAXUS-IV Investigators. Impact of routine angiographic follow-up on the clinical benefits of paclitaxel-eluting stents: results from the TAXUS-IV trial. J Am Coll Cardiol 2006;48:32 6. Key Words: percutaneous coronary intervention STsegment elevation myocardial infarction drug-eluting stents.
Original Article. Division of Cardiology, AOU Maggiore della Carità Eastern Piedmont University, Novara, Italy 2
592252DVR0010.1177/1479164115592252Diabetes & Vascular Disease ResearchDe Luca et al. research-article2015 Original Article Impact of diabetes on the benefits from everolimus-eluting stent as compared
More informationA Large Prospective Randomized Trial of DES vs BMS in Patients with STEMI
HORIZONS-AMI: A Large Prospective Randomized Trial of DES vs BMS in Patients with STEMI Gregg W. Stone MD Columbia University Medical Center Cardiovascular Research Foundation Disclosures Gregg W. Stone
More informationMaintenance of Long-Term Clinical Benefit With Sirolimus-Eluting Stents in Patients With ST-Segment Elevation Myocardial Infarction
Journal of the American College of Cardiology Vol. 55, No. 8, 2010 2010 by the American College of Cardiology Foundation ISSN 0735-1097/10/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2009.09.046
More informationAbstract Background: Methods: Results: Conclusions:
Two-Year Clinical and Angiographic Outcomes of Overlapping Sirolimusversus Paclitaxel- Eluting Stents in the Treatment of Diffuse Long Coronary Lesions Kang-Yin Chen 1,2, Seung-Woon Rha 1, Yong-Jian Li
More informationEffect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial
Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki Hong, MD. PhD on behalf of the IVUS-XPL trial investigators
More informationPROMUS Element Experience In AMC
Promus Element Luncheon Symposium: PROMUS Element Experience In AMC Jung-Min Ahn, MD. University of Ulsan College of Medicine, Heart Institute, Asan Medical Center, Seoul, Korea PROMUS Element Clinical
More informationNine-year clinical outcomes of drug-eluting stents vs. bare metal stents for large coronary vessel lesions
Journal of Geriatric Cardiology (2017) 14: 35 41 2017 JGC All rights reserved; www.jgc301.com Research Article Open Access Nine-year clinical outcomes of drug-eluting stents vs. bare metal stents for large
More informationJournal of the American College of Cardiology Vol. 47, No. 7, by the American College of Cardiology Foundation ISSN /06/$32.
Journal of the American College of Cardiology Vol. 47, No. 7, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.05.102
More informationLM stenting - Cypher
LM stenting - Cypher Left main stenting with BMS Since 1995 Issues in BMS era AMC Restenosis and TLR (%) 3 27 TLR P=.282 Restenosis P=.71 28 2 1 15 12 Ostium 5 4 Shaft Bifurcation Left main stenting with
More informationDES in Diabetic Patients
DES in Diabetic Patients Charles Chan, M.D., FACC Gleneagles Hospital Singapore TCT ASIA PACIFIC 2007 Why do diabetics have worse outcome after PCI? More extensive atherosclerosis and diffuse disease Increase
More informationPaclitaxel-Eluting versus Uncoated Stents in Primary Percutaneous Coronary Intervention
original article Paclitaxel-Eluting versus Uncoated Stents in Primary Percutaneous Coronary Intervention Gerrit J. Laarman, M.D., Ph.D., Maarten J. Suttorp, M.D., Ph.D., Maurits T. Dirksen, M.D., Loek
More informationMULTIcentre evaluation of Single high-dose. acute myocardial infarction study
MULTIcentre evaluation of Single high-dose Tirofiban bolus TiRofiban vs. versus with sirolimus eluting stent or barein metal stent in during primary PCI STEMI acute myocardial infarction study M. Valgimigli,
More informationEffect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary PCI
Effect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary PCI Dr Sasha Koul, MD Dept of Cardiology, Lund University Hospital, Lund, Sweden
More informationUnprotected LM intervention
Unprotected LM intervention Guideline for COMBAT Seung-Jung Park, MD, PhD Professor of Internal Medicine, Seoul, Korea Current Recommendation for unprotected LMCA Stenosis Class IIb C in ESC guideline
More informationSupplementary Table S1: Proportion of missing values presents in the original dataset
Supplementary Table S1: Proportion of missing values presents in the original dataset Variable Included (%) Missing (%) Age 89067 (100.0) 0 (0.0) Gender 89067 (100.0) 0 (0.0) Smoking status 80706 (90.6)
More informationPaclitaxel-Eluting Coronary Stents in Patients With Diabetes Mellitus
Journal of the American College of Cardiology Vol. 51, No. 7, 2008 2008 by the American College of Cardiology Foundation ISSN 0735-1097/08/$34.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2007.10.035
More informationThe MAIN-COMPARE Study
Long-Term Outcomes of Coronary Stent Implantation versus Bypass Surgery for the Treatment of Unprotected Left Main Coronary Artery Disease Revascularization for Unprotected Left MAIN Coronary Artery Stenosis:
More informationPCI for In-Stent Restenosis. CardioVascular Research Foundation
PCI for In-Stent Restenosis ISR of BMS Patterns of In-Stent Restenosis Pattern I : Focal Type IA: Articulation / Gap Type IB: Marginal Type IC: Focal body Type ID: Multifocal Pattern II,III,IV : Diffuse
More informationKomplexe Koronarintervention heute: Von Syntax zu bioresorbierbaren Stents
Komplexe Koronarintervention heute: Von Syntax zu bioresorbierbaren Stents Prof. Dr. med. Julinda Mehilli Medizinische Klinik und Poliklinik I Klinikum der Universität München Campus Großhadern Key Factors
More informationPCI for Long Coronary Lesion
PCI for Long Coronary Lesion Shift of a General Idea with the Introduction of DES In the Bare Metal Stent Era Higher Restenosis Rate With Increasing Stent Length and Decreasing Stent Area Restenosis.6.4.2
More informationOptimal antiplatelet and anticoagulant therapy for patients treated in STEMI network
Torino 6 Joint meeting with Mayo Clinic Great Innovation in Cardiology 14-15 Ottobre 2010 Optimal antiplatelet and anticoagulant therapy for patients treated in STEMI network Diego Ardissino Ischemic vs
More informationClinical Investigations
Clinical Investigations Clinical Outcomes for Single Stent and Multiple Stents in Contemporary Practice Qiao Shu Bin, MD; Liu Sheng Wen, MD; Xu Bo, BS; Chen Jue, MD; Liu Hai Bo, MD; Yang Yue Jin, MD; Chen
More informationSupplementary Material to Mayer et al. A comparative cohort study on personalised
Suppl. Table : Baseline characteristics of the patients. Characteristic Modified cohort Non-modified cohort P value (n=00) Age years 68. ±. 69.5 ±. 0. Female sex no. (%) 60 (0.0) 88 (.7) 0.0 Body Mass
More informationbivalirudin 250mg powder for concentrate for solution for injection or infusion (Angiox) SMC No. (638/10) The Medicines Company
bivalirudin 250mg powder for concentrate for solution for injection or infusion (Angiox) SMC No. (638/10) The Medicines Company 06 August 2010 The Scottish Medicines Consortium (SMC) has completed its
More informationClinical Seminar. Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective
Clinical Seminar Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical
More informationCase Report Primary Percutaneous Coronary Intervention in an Acute Myocardial Infarction Due to the Occlusion of the Left Main Coronary Artery
Hellenic J Cardiol 48: 368-372, 2007 Case Report Primary Percutaneous Coronary Intervention in an Acute Myocardial Infarction Due to the Occlusion of the Left Main Coronary Artery STELIOS PARASKEVAIDIS,
More informationInfluence of Planned Six-Month Follow-Up Angiography on Late Outcome After Percutaneous Coronary Intervention A Randomized Study
Journal of the American College of Cardiology Vol. 38, No. 4, 2001 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00 Published by Elsevier Science Inc. PII S0735-1097(01)01476-0 Influence
More informationJournal of the American College of Cardiology Vol. 55, No. 9, by the American College of Cardiology Foundation ISSN /10/$36.
Journal of the American College of Cardiology Vol. 55, No. 9, 2010 2010 by the American College of Cardiology Foundation ISSN 0735-1097/10/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2009.09.052
More informationTitan versus TAXUS Stents at 1 Year Clinical Outcome
Original Article Titan versus TAXUS Stents at 1 Year Clinical Outcome Acta Cardiol Sin 2011;27:94 100 Interventional Cardiology One-Year Follow-Up after Percutaneous Coronary Intervention with Titanium-Nitride-Oxide-Coated
More informationLessons learned From The National PCI Registry
Lessons learned From The National PCI Registry w a v e On Behalf of The Publication Committee of the National PCI Registry Objectives & Anticipated Achievements To determine the epidemiology of patients
More informationPrevention of Coronary Stent Thrombosis and Restenosis
Prevention of Coronary Stent Thrombosis and Restenosis Seong-Wook Park, MD, PhD, FACC Division of Cardiology, Asan Medical Center University of Ulsan College of Medicine, Seoul, Korea 9/12/03 Coronary
More informationHCS Working Group Seminars Macedonia Pallas Hotel, Friday 21 st February Drug-eluting stents Are they all equal?
HCS Working Group Seminars Macedonia Pallas Hotel, Friday 21 st February 2014 Drug-eluting stents Are they all equal? Vassilis Spanos Interventional Cardiologist, As. Director 3 rd Cardiology Clinic Euroclinic
More informationISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions
Julinda Mehilli, MD Deutsches Herzzentrum Technische Universität Munich Germany ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions Background Left main
More informationRandomized Comparison of Prasugrel and Bivalirudin versus Clopidogrel and Heparin in Patients with ST-Segment Elevation Myocardial Infarction
Randomized Comparison of Prasugrel and Bivalirudin versus Clopidogrel and Heparin in Patients with ST-Segment Elevation Myocardial Infarction The Bavarian Reperfusion Alternatives Evaluation (BRAVE) 4
More informationST-Elevation MI: Update on Bivalirudin and DES
ST-Elevation MI: Update on Bivalirudin and DES George D. Dangas, MD, FACC, FSCAI, FAHA Professor of Medicine Director, Cardiovascular Innovation Mount Sinai Medical Center, New York, NY Disclosure Research
More informationStent Thrombosis: Patient, Procedural, and Stent Factors. Eugene Mc Fadden Cork, Ireland
Stent Thrombosis: Patient, Procedural, and Stent Factors Eugene Mc Fadden Cork, Ireland Definitions Early 1 yr TAXUS >6months CYPHER Incidence and Timing BMS Registry data
More informationTCTAP Upendra Kaul MD,DM,FACC,FSCAI,FAMS,FCSI
Indian TUXEDO Trial In Medically Treated Diabetics Upendra Kaul MD,DM,FACC,FSCAI,FAMS,FCSI Executive Director and Dean Escorts Heart Institute & Medical Research Center and Fortis Hospitals, New Delhi
More informationTarget vessel only revascularization versus complet revascularization in non culprit lesions in acute myocardial infarction treated by primary PCI
Target vessel only revascularization versus complet revascularization in non culprit lesions in acute myocardial infarction treated by primary PCI Gamal Abdelhady, Emad Mahmoud Department of interventional
More information2010 Korean Society of Cardiology Spring Scientific Session Korea Japan Joint Symposium. Seoul National University Hospital Cardiovascular Center
2010 Korean Society of Cardiology Spring Scientific Session Korea Japan Joint Symposium Does Lt Late Cth Catch up Exist Eiti in DES? : Quantitative Coronary Angiography Analysis Kyung Woo Park, MD Cardiovascular
More informationTreatment of Left Main Coronary Trifurcation Lesions with the Paclitaxel Drug-Eluting Stent: Mid-Term Outcomes from a Tertiary Medical Center
Original Contribution Treatment of Left Main Coronary Trifurcation Lesions with the Paclitaxel Drug-Eluting Stent: Mid-Term Outcomes from a Tertiary Medical Center Nicolas W. Shammas, MD, MS, Gail A. Shammas,
More informationJournal of the American College of Cardiology Vol. 51, No. 6, by the American College of Cardiology Foundation ISSN /08/$34.
Journal of the American College of Cardiology Vol. 51, No. 6, 2008 2008 by the American College of Cardiology Foundation ISSN 0735-1097/08/$34.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2007.09.056
More information1. Diabetes mellitus (DM) is associated with worse clinical and angiographic outcomes even in acute myocardial Infarction (AMI) patients.
Midterm Clinical Outcomes of Insulin Requiring Diabetes Mellitus versus Non-insulin Dependent Diabetes Mellitus in Acute Myocardial Infarction Patients in Drug Eluting Stent Era : Insight from Korea Acute
More informationDrug Eluting Stents Sometimes Fail ESC Stockholm 29 Set 2010 Stent Thrombosis Alaide Chieffo
Drug Eluting Stents Sometimes Fail ESC Stockholm 29 Set 2010 Stent Thrombosis 11.45-12.07 Alaide Chieffo San Raffaele Scientific Institute, Milan, Italy Historical Perspective 25 20 15 10 5 0 Serruys 1991
More informationP rimary angioplasty currently represents
Cardiovascular and Metabolic Risk O R I G I N A L A R T I C L E Impact of Diabetes on Long-Term Outcome After Primary Angioplasty Insights from the DESERT cooperation GIUSEPPE DE LUCA, MD 1 MAURITS T.
More informationThe titanium nitride oxide stent an alternative to DES. Adam de Belder MD FRCP Sussex Cardiac Centre BSUH on behalf of Hexacath
The titanium nitride oxide stent an alternative to DES Adam de Belder MD FRCP Sussex Cardiac Centre BSUH on behalf of Hexacath Advanced Angioplasty 2008 Declaration of interest I have received an honorarium
More informationANGIOPLASY SUMMIT 2007 TCT ASIA PACIFIC. Seoul, Korea: April The problem is exaggerated: Data from Real World Registries
ANGIOPLASY SUMMIT 007 TCT ASIA PACIFIC Seoul, Korea: 5-7 7 April 007 15 min Plenary Session: State-of of-the-art Lectures The problem is exaggerated: Data from Real World Registries Antonio Colombo Centro
More informationRole of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University
Role of Clopidogrel in Acute Coronary Syndromes Hossam Kandil,, MD Professor of Cardiology Cairo University ACS Treatment Strategies Reperfusion/Revascularization Therapy Thrombolysis PCI (with/ without
More informationSeQuent Please World Wide Registry
Journal of the American College of Cardiology Vol. 6, No. 18, 212 212 by the American College of Cardiology Foundation ISSN 735-197/$36. Published by Elsevier Inc. http://dx.doi.org/1.116/j.jacc.212.7.4
More informationAntiplatelet therapy in myocardial infarction and coronary stent thrombosis Heestermans, Antonius Adrianus Cornelius Maria
University of Groningen Antiplatelet therapy in myocardial infarction and coronary stent thrombosis Heestermans, Antonius Adrianus Cornelius Maria IMPORTANT NOTE: You are advised to consult the publisher's
More information1. Whether the risks of stent thrombosis (ST) and major adverse cardiovascular and cerebrovascular events (MACCE) differ from BMS and DES
1 Comparison of Ischemic and Bleeding Events After Drug- Eluting Stents or Bare Metal Stents in Subjects Receiving Dual Antiplatelet Therapy: Results from the Randomized Dual Antiplatelet Therapy (DAPT)
More informationComparison of Bare metal Vs Drug eluting stents for in-stent Restenosis among Diabetics
Original Article Comparison of Bare metal Vs Drug eluting stents for in-stent Restenosis among Diabetics Mynuddin Ahmed Nawaz 1, Ia Avaliani 1, Irakli Davitashvili 1, Georgi Getmansky 1 Khatuna Jalabadze
More informationJournal of the American College of Cardiology Vol. 48, No. 2, by the American College of Cardiology Foundation ISSN /06/$32.
Journal of the American College of Cardiology Vol. 48, No. 2, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2006.03.039
More informationWhat is the Optimal Triple Anti-platelet Therapy Duration in Patients with Acute Myocardial Infarction Undergoing Drug-eluting Stents Implantation?
What is the Optimal Triple Anti-platelet Therapy Duration in Patients with Acute Myocardial Infarction Undergoing Drug-eluting Stents Implantation? Keun-Ho Park, Myung Ho Jeong, Min Goo Lee, Jum Suk Ko,
More informationOutcomes With the Paclitaxel-Eluting Stent in Patients With Acute Coronary Syndromes Analysis From the TAXUS-IV Trial
Journal of the American College of Cardiology Vol. 45, No. 8, 2005 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2004.10.074
More informationBern-Rotterdam Cohort Study
Bern-Rotterdam Cohort Study Newer generation everolimus-eluting stents eliminate the risk of very late stent thrombosis compared with early generation sirolimus-eluting and paclitaxel-eluting stents Lorenz
More informationPeriprocedural Myocardial Infarction and Clinical Outcome In Bifurcation Lesion
Periprocedural Myocardial Infarction and Clinical Outcome In Bifurcation Lesion Hyeon-Cheol Gwon Cardiac and Vascular Center Samsung Medical Center Sungkyunkwan University School of Medicine Dr. Hyeon-Cheol
More informationINDEX 1 INTRODUCTION DEVICE DESCRIPTION CLINICAL PROGRAM FIRST-IN-MAN CLINICAL INVESTIGATION OF THE AMAZONIA SIR STENT...
May 2017 INDEX 1 INTRODUCTION... 2 2 DEVICE DESCRIPTION... 3 ANTI-PROLIFERATIVE DRUG - SIROLIMUS... 3 BIODEGRADABLE POLYMERS... 3 SIROLIMUS CONTROLLED ELUTION... 4 STENT PLATFORM... 4 3 CLINICAL PROGRAM...
More informationStephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland
Advances in Antiplatelet Therapy in PCI and ACS Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland Targets for Platelet
More informationCulprit Lesion Remodeling and Long-term (> 5years) Prognosis in Patients with Acute Coronary Syndrome
Culprit Lesion Remodeling and Long-term (> 5years) Prognosis in Patients with Acute Coronary Syndrome Hiroyuki Okura*, MD; Nobuya Matsushita**,MD Kenji Shimeno**, MD; Hiroyuki Yamaghishi**, MD Iku Toda**,
More informationCoronary Artery Bypass Grafting Versus Coronary Implantation of Sirolimus-Eluting Stents in Patients with Diabetic Retinopathy
Coronary Artery Bypass Grafting Versus Coronary Implantation of Sirolimus-Eluting Stents in Patients with Diabetic Retinopathy Takayuki Ohno, MD, Shinichi Takamoto, MD, Noboru Motomura, MD, Minoru Ono,
More informationFacilitated Percutaneous Coronary Intervention in Acute Myocardial Infarction. Is it beneficial to patients?
Facilitated Percutaneous Coronary Intervention in Acute Myocardial Infarction Is it beneficial to patients? Seung-Jea Tahk, MD. PhD. Suwon, Korea Facilitated PCI.. background Degree of coronary flow at
More informationJournal of the American College of Cardiology Vol. 47, No. 8, by the American College of Cardiology Foundation ISSN /06/$32.
Journal of the American College of Cardiology Vol. 47, No. 8, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.11.066
More informationLeft Main and Bifurcation Summit I. Lessons from European LM Studies
Left Main and Bifurcation Summit I Apr 29 8.56-9.09 Lessons from European LM Studies Alaide Chieffo, MD S. Raffaele Hospital, Milan, Italy Nothing to disclose regarding this presentation Lesion Location
More informationNew Generation Drug- Eluting Stent in Korea
New Generation Drug- Eluting Stent in Korea Young-Hak Kim, MD, PhD Department of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea Purpose To briefly introduce the
More informationSirolimus- Versus Paclitaxel-Eluting Stents for the Treatment of Coronary Bifurcations
Journal of the American College of Cardiology Vol. 55, No. 16, 2010 2010 by the American College of Cardiology Foundation ISSN 0735-1097/10/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2010.02.008
More informationDEB experience in Gachon Universtiy Gil Hospital (in ISR) Soon Yong Suh MD., PhD. Heart Center Gachon University Gil Hospital Seoul, Korea.
DEB experience in Gachon Universtiy Gil Hospital (in ISR) Soon Yong Suh MD., PhD. Heart Center Gachon University Gil Hospital Seoul, Korea. In-stent restenosis (ISR) Remains important issue even in the
More informationPrimary PCI versus thrombolytic therapy: long-term follow-up according to infarct location
Heart Online First, published on April 14, 2005 as 10.1136/hrt.2005.060152 1 Primary PCI versus thrombolytic therapy: long-term follow-up according to infarct location Short running head: Anterior infarction
More informationClinical Study Age Differences in Long Term Outcomes of Coronary Patients Treated with Drug Eluting Stents at a Tertiary Medical Center
Aging Research Volume 2013, Article ID 471026, 4 pages http://dx.doi.org/10.1155/2013/471026 Clinical Study Age Differences in Long Term Outcomes of Coronary Patients Treated with Drug Eluting Stents at
More informationOne-Year Clinical Outcomes after Sirolimus-Eluting Coronary Stent Implantation for Acute Myocardial Infarction in the Worldwide e-select Registry
C 2012, Wiley Periodicals, Inc. DOI: 10.1111/j.1540-8183.2011.00705.x One-Year Clinical Outcomes after Sirolimus-Eluting Coronary Stent Implantation for Acute Myocardial Infarction in the Worldwide e-select
More informationPercutaneous Intervention of Unprotected Left Main Disease
Percutaneous Intervention of Unprotected Left Main Disease Technical feasibility and Clinical outcomes Seung-Jung Park, MD, PhD, FACC Professor of Internal Medicine Asan Medical Center, Seoul, Korea Unprotected
More informationBivalirudin Clinical Trials Update Evidence and Future Perspectives
Bivalirudin Clinical Trials Update Evidence and Future Perspectives Andreas Baumbach Consultant Cardiologist/ hon. Reader in Cardiology Bristol Heart Institute University Hospitals Bristol MY CONFLICTS
More informationKorea University Guro Hospital, Seoul, Korea * Chonnam National University Hospital, Gwangju, Korea
Left Main Disease versus Non Left Main Disease in Acute Myocardial Infarction Patients in Real world Clinical Practice : Lessons from Korea Acute Myocardial Infarction Registry (KAMIR) Seung-Woon Rha*,
More informationLong-Term Comparison of Everolimus-Eluting and Sirolimus-Eluting Stents for Coronary Revascularization
Journal of the American College of Cardiology Vol. 57, No. 21, 2011 2011 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2011.01.023
More informationA Randomized Comparison of Clopidogrel and Aspirin Versus Ticlopidine and Aspirin After the Placement of Coronary Artery Stents
Journal of the American College of Cardiology Vol. 41, No. 6, 2003 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Science Inc. doi:10.1016/s0735-1097(02)02974-1
More informationReview Article Comparison of 12-Month Outcomes with Zotarolimus- and Paclitaxel-Eluting Stents: A Meta-Analysis
International Scholarly Research Network ISRN Cardiology Volume 2011, Article ID 675638, 6 pages doi:10.5402/2011/675638 Review Article Comparison of 12-Month Outcomes with Zotarolimus- and Paclitaxel-Eluting
More informationA Meta-Analysis Of Randomized Controlled Trials With Coronary Drug-Eluting Stents Compared With Bare-Metal Stents
ISPUB.COM The Internet Journal of Cardiology Volume 3 Number 2 A Meta-Analysis Of Randomized Controlled Trials With Coronary Drug-Eluting Stents Compared With Bare-Metal Stents M Sondhi, A Jagannath, J
More informationUnprotected Left Main Coronary Artery Disease in Patients With Low Predictive Risk of Mortality
Unprotected Left Main Coronary Artery Disease in Patients With Low Predictive Risk of Mortality Shun Watanabe, MD, Tatsuhiko Komiya, MD, Genichi Sakaguchi, MD, PhD, and Takeshi Shimamoto, MD, PhD Department
More informationDES In-stent Restenosis
DES In-stent Restenosis Roxana Mehran, MD Columbia University Medical Center The Cardiovascular Research Foundation DES Restenosis Mechanisms Predictors Morphological patterns Therapy approach Mechanisms
More informationAngiographic Stent Thrombosis at Coronary Bifurcations
JACC: CARDIOVASCULAR INTERVENTIONS VOL. 5, NO. 1, 2012 2012 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/$36.00 PUBLISHED BY ELSEVIER INC. DOI: 10.1016/j.jcin.2011.09.015 Angiographic
More informationStent Thrombosis in Bifurcation Stenting
Summit TCT Asia Pacific 2009 Stent Thrombosis in Bifurcation Stenting Associate Professor Tan Huay Cheem MBBS, M Med(Int Med), MRCP, FRCP(UK), FAMS, FACC, FSCAI Director, National University Heart Centre,
More informationDiabetic Patients: Current Evidence of Revascularization
Diabetic Patients: Current Evidence of Revascularization Alexandra J. Lansky, MD Yale University School of Medicine University College of London The Problem with Diabetic Patients Endothelial dysfunction
More informationSafety of Single- Versus Multi-vessel Angioplasty for Patients with AMI and Multi-vessel CAD
Safety of Single- Versus Multi-vessel Angioplasty for Patients with AMI and Multi-vessel CAD Mun K. Hong, MD Associate Professor of Medicine Director, Cardiovascular Intervention and Research Weill Cornell
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/21543 holds various files of this Leiden University dissertation Author: Dharma, Surya Title: Perspectives in the treatment of cardiovascular disease :
More informationThe MAIN-COMPARE Registry
Long-Term Outcomes of Coronary Stent Implantation versus Bypass Surgery for the Treatment of Unprotected Left Main Coronary Artery Disease Revascularization for Unprotected Left MAIN Coronary Artery Stenosis:
More informationLearning Objectives. Epidemiology of Acute Coronary Syndrome
Cardiovascular Update: Antiplatelet therapy in acute coronary syndromes PHILLIP WEEKS, PHARM.D., BCPS-AQ CARDIOLOGY Learning Objectives Interpret guidelines as they relate to constructing an antiplatelet
More informationIntra-Procedural Stent Thrombosis
JACC: CARDIOVASCULAR INTERVENTIONS VOL. 6, NO. 1, 2013 2013 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/$36.00 PUBLISHED BY ELSEVIER INC. http://dx.doi.org/10.1016/j.jcin.2012.08.018
More informationEXAMINATION trial. Manel Sabaté Hospital Clínic, Barcelona (On behalf of the Examination Investigators)
Manel Sabaté Hospital Clínic, Barcelona (On behalf of the Examination Investigators) Disclosures Investigator Initiated Trial: NCT00828087. Unrestricted grant from Abbott to the Spanish Heart Foundation.
More informationPCI for LMCA lesions A Review of latest guidelines and relevant evidence
HCS Working Group Seminars Met Hotel, Thursday 14 th February 2013 PCI for LMCA lesions A Review of latest guidelines and relevant evidence Vassilis Spanos Interventional Cardiologist, As. Director 3 rd
More informationJournal of the American College of Cardiology Vol. 46, No. 5, by the American College of Cardiology Foundation ISSN /05/$30.
Journal of the American College of Cardiology Vol. 46, No. 5, 2005 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.06.009
More informationChristian Spaulding. for the TYPHOON Investigators
Four-Year Follow-Up of the TYPHOON Study, a Multicenter, Randomized, Single-blind Trial To Assess The Use of the CYPHER Sirolimus-eluting Stent (SES) in Acute Myocardial Infarction Patients Treated With
More informationSTEMI AND MULTIVESSEL CORONARY DISEASE
STEMI AND MULTIVESSEL CORONARY DISEASE ΤΣΙΑΦΟΥΤΗΣ Ν. ΙΩΑΝΝΗΣ ΕΠΕΜΒΑΤΙΚΟΣ ΚΑΡΔΙΟΛΟΓΟΣ Α ΚΑΡΔΙΟΛΟΓΙΚΗ ΝΟΣ ΕΡΥΘΡΟΥ ΣΤΑΥΡΟΥ IRA 30-50% of STEMI patients have additional stenoses other than the infarct related
More informationST-Segment Elevation Myocardial Infarction Due to Early and Late Stent Thrombosis
Journal of the American College of Cardiology Vol. 51, No. 25, 2008 2008 by the American College of Cardiology Foundation ISSN 0735-1097/08/$34.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2008.01.070
More informationRationale for Percutaneous Revascularization ESC 2011
Rationale for Percutaneous Revascularization Marie Claude Morice, Massy FR MD, FESC, FACC ESC 2011 Paris Villepinte - 27-31 August, 2011 Massy, France Potential conflicts of interest I have the following
More informationBelinda Green, Cardiologist, SDHB, 2016
Acute Coronary syndromes All STEMI ALL Non STEMI Unstable angina Belinda Green, Cardiologist, SDHB, 2016 Thrombus in proximal LAD Underlying pathophysiology Be very afraid for your patient Wellens
More informationUpdated and Guideline Based Treatment of Patients with STEMI
Updated and Guideline Based Treatment of Patients with STEMI Eli I. Lev, MD Director, Cardiac Catheterization Laboratory Hasharon Hospital, Rabin Medical Center Associate Professor of Cardiology Tel-Aviv
More information2-Year Follow-Up of a Randomized Controlled Trial of Everolimus- and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice
Journal of the American College of Cardiology Vol. 58, No. 1, 2011 2011 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2011.02.023
More informationAre Asian Patients Different? - Updates Of Biomatrix Experience In Regional Settings: BEACON II (3 Yr F up) &
Are Asian Patients Different? - Updates Of Biomatrix Experience In Regional Settings: BEACON II (3 Yr F up) & Biomatrix TM Single Center Experience (Indonesia)(Final 5 Yr F up) T. Santoso University of
More information388-1 Poongnap-dong, Songpa-gu, Seoul, , Republic of Korea b Department of Medicine, Changi General Hospital, Singapore
International Journal of Cardiology 126 (2008) 224 228 www.elsevier.com/locate/ijcard Percutaneous coronary intervention with stenting of left main coronary artery with drug-eluting stent in the setting
More informationImpact of Chronic Kidney Disease on Long-Term Outcome in Coronary Bypass Candidates Treated with Percutaneous Coronary Intervention
Original Article Print ISSN 1738-5520 On-line ISSN 1738-5555 Korean Circulation Journal Impact of Chronic Kidney Disease on Long-Term Outcome in Coronary Bypass Candidates Treated with Percutaneous Coronary
More information